180
Participants
Start Date
February 1, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
March 30, 2026
RCT2100
RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
Placebo
Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
RCT2100
RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks
RCT2100
RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks
RECRUITING
New York Medical College, Valhalla
RECRUITING
University of Pittsburgh, Pittsburgh
RECRUITING
The University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Emory University, Atlanta
RECRUITING
The University of Alabama at Birmingham, Birmingham
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
National Jewish Health, Denver
RECRUITING
University of Arizona, Tucson
RECRUITING
UCSD, San Diego
RECRUITING
Stanford University, Palo Alto
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
University of Washington, Seattle
RECRUITING
Boston Children's Hospital, Boston
RECRUITING
Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier
RECRUITING
Hôpital Necker Enfants Malades, Paris
RECRUITING
UMC Utrecht, Utrecht
COMPLETED
New Zealand Clinical Research (Part 1 Only), Auckland
RECRUITING
University Hospitals Birmingham, Birmingham
RECRUITING
Royal Papworth Hospital, Cambridge
RECRUITING
Leeds Teaching Hospitals, Leeds
RECRUITING
King's College Hospital, London
RECRUITING
Nottingham University Hospitals, Nottingham
RECRUITING
University Hospital Southampton, Southampton
Lead Sponsor
ReCode Therapeutics
INDUSTRY